The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
15-keto-5,8,11,13-eicosatetraenoic acid results in decreased expression of TNF mRNA 15-keto-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
ALAD protein results in increased metabolism of Aminolevulinic Acid Bilirubin inhibits the reaction [Aminolevulinic Acid results in increased activity of ALAD protein] ALAD gene SNP affects the reaction [ALAD protein results in increased metabolism of Aminolevulinic Acid]
Aminolevulinic Acid results in decreased expression of ALAS1 mRNA Aminolevulinic Acid results in increased activity of ALAS1 protein Bilirubin inhibits the reaction [Aminolevulinic Acid results in increased activity of ALAS1 protein]
Aminolevulinic Acid analog results in increased activity of CASP8 protein pyrazolanthrone inhibits the reaction [Aminolevulinic Acid analog results in increased activity of CASP8 protein]
pyrazolanthrone inhibits the reaction [Aminolevulinic Acid analog results in increased activity of CASP9 protein] 3-methyladenine inhibits the reaction [Aminolevulinic Acid analog results in increased activity of CASP9 protein]
Aminolevulinic Acid results in decreased activity of CAT protein Bilirubin inhibits the reaction [Aminolevulinic Acid results in decreased activity of CAT protein]
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Aminolevulinic Acid analog results in increased phosphorylation of FADD protein]; FADD mutant form inhibits the reaction [Aminolevulinic Acid analog results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Aminolevulinic Acid analog results in increased phosphorylation of FADD protein]
Aminolevulinic Acid results in decreased activity of GPX1 protein Bilirubin inhibits the reaction [Aminolevulinic Acid results in decreased activity of GPX1 protein]
NFE2L2 gene mutant form promotes the reaction [Aminolevulinic Acid results in increased expression of HMOX1 mRNA] Bilirubin inhibits the reaction [Aminolevulinic Acid results in increased activity of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [Aminolevulinic Acid results in increased activity of HMOX1 protein]
Aminolevulinic Acid affects the expression of MMP1 mRNA; Aminolevulinic Acid affects the expression of MMP1 protein Sodium Azide inhibits the reaction [Aminolevulinic Acid affects the expression of MMP1 protein]
Aminolevulinic Acid analog results in increased activity of MMP2 protein Chitosan inhibits the reaction [Aminolevulinic Acid analog results in increased activity of MMP2 protein]
Aminolevulinic Acid affects the expression of MMP3 mRNA; Aminolevulinic Acid affects the expression of MMP3 protein Sodium Azide inhibits the reaction [Aminolevulinic Acid affects the expression of MMP3 protein]
NFE2L2 gene mutant form inhibits the reaction [Aminolevulinic Acid results in increased expression of CYP2A5 mRNA]; NFE2L2 gene mutant form promotes the reaction [Aminolevulinic Acid results in increased expression of HMOX1 mRNA]
Aminolevulinic Acid results in decreased activity of SOD1 protein Bilirubin inhibits the reaction [Aminolevulinic Acid results in decreased activity of SOD1 protein]
Aminolevulinic Acid results in decreased activity of UROD protein Hexachlorobenzene promotes the reaction [Aminolevulinic Acid results in decreased activity of UROD protein]
leptomycin B inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; leptomycin B inhibits the reaction [Formaldehyde affects the phosphorylation of AKT1 protein]; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of AKT1 protein] leptomycin B results in increased phosphorylation of AKT1 protein
leptomycin B affects the localization of BACH1 protein leptomycin B inhibits the reaction [Cannabidiol results in decreased expression of BACH1 protein] leptomycin B inhibits the reaction [Cadmium Chloride affects the localization of BACH1 protein]; leptomycin B inhibits the reaction [Cadmium results in decreased activity of BACH1 protein]
[epigallocatechin gallate co-treated with leptomycin B] results in decreased expression of BIRC5 mRNA; [epigallocatechin gallate co-treated with leptomycin B] results in decreased expression of BIRC5 protein; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of BIRC5 mRNA; leptomycin B promotes the reaction [gefitinib results in decreased expression of BIRC5 protein]; TP53 gene mutant form inhibits the reaction [leptomycin B results in decreased expression of BIRC5 protein] leptomycin B results in decreased expression of BIRC5 mRNA; leptomycin B results in decreased expression of BIRC5 protein
[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of BRCA1 mRNA leptomycin B results in decreased expression of BRCA1 mRNA
leptomycin B results in increased secretion of CCL2 protein polydatin inhibits the reaction [leptomycin B results in increased secretion of CCL2 protein]
[epigallocatechin gallate co-treated with leptomycin B] results in increased expression of CDKN1A mRNA; [epigallocatechin gallate co-treated with leptomycin B] results in increased expression of CDKN1A protein; leptomycin B inhibits the reaction [gefitinib results in decreased expression of CDKN1A protein]; TP53 gene mutant form inhibits the reaction [leptomycin B results in increased expression of CDKN1A protein] leptomycin B results in increased expression of CDKN1A mRNA; leptomycin B results in increased expression of CDKN1A protein
leptomycin B results in decreased secretion of CXCL10 protein acteoside promotes the reaction [leptomycin B results in decreased secretion of CXCL10 protein]; Quercetin promotes the reaction [leptomycin B results in decreased secretion of CXCL10 protein]
leptomycin B results in increased expression of CYP3A4 mRNA [epigallocatechin gallate co-treated with leptomycin B] results in increased expression of CYP3A4 mRNA
[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of DNMT1 mRNA leptomycin B results in decreased expression of DNMT1 mRNA
leptomycin B inhibits the reaction [EGF protein affects the localization of SET protein alternative form]; leptomycin B inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]
leptomycin B results in increased expression of GPX1 mRNA [epigallocatechin gallate co-treated with leptomycin B] results in increased expression of GPX1 mRNA
leptomycin B results in increased phosphorylation of MAPK1 protein leptomycin B inhibits the reaction [gefitinib results in decreased phosphorylation of MAPK1 protein]
leptomycin B inhibits the reaction [gefitinib results in decreased phosphorylation of MAPK3 protein] leptomycin B results in increased phosphorylation of MAPK3 protein
leptomycin B affects the localization of RANBP1 protein leptomycin B inhibits the reaction [Phenylephrine affects the localization of and affects the expression of RANBP1 protein]
leptomycin B affects the reaction [Formaldehyde affects the localization of SET protein alternative form]; leptomycin B inhibits the reaction [EGF protein affects the localization of SET protein alternative form]
leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]; leptomycin B inhibits the reaction [arsenite inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]
leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]; leptomycin B inhibits the reaction [arsenite inhibits the reaction [XPO4 protein results in increased export of SMAD3 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [XPO4 protein results in increased export of SMAD3 protein]]
leptomycin B results in increased expression of SOD2 mRNA [epigallocatechin gallate co-treated with leptomycin B] results in increased expression of SOD2 mRNA
leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]; leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]
3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [leptomycin B results in increased expression of TP53 protein]; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of BRCA1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of CHEK2 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of DNMT1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of HK2 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of MDM4 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of PRKCA mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of TP63 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of APAF1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of BIRC5 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of IL6 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of NFKB1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of TNFRSF10D mRNA; [sodium arsenite co-treated with leptomycin B] results in increased phosphorylation of TP53 protein; leptomycin B affects the localization of and results in decreased degradation of TP53 protein; leptomycin B inhibits the reaction [Cycloheximide results in increased degradation of TP53 protein]; leptomycin B inhibits the reaction [sodium arsenite affects the localization of TP53 protein]; leptomycin B inhibits the reaction [sodium arsenite results in increased degradation of TP53 protein mutant form]; leptomycin B inhibits the reaction [TP53 protein results in increased susceptibility to trichostatin A]; PCB 180 promotes the reaction [leptomycin B results in increased expression of TP53 protein]; Pravastatin inhibits the reaction [leptomycin B results in decreased degradation of TP53 protein]; TP53 gene mutant form inhibits the reaction [leptomycin B results in decreased expression of BIRC5 protein]; TP53 gene mutant form inhibits the reaction [leptomycin B results in increased expression of CDKN1A protein] leptomycin B affects the expression of TP53 protein alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [leptomycin B results in increased expression of TP53 protein]]; Tetrachlorodibenzodioxin inhibits the reaction [leptomycin B results in increased expression of TP53 protein] TP53 gene mutant form results in increased susceptibility to leptomycin B
[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of TP63 mRNA leptomycin B results in decreased expression of TP63 mRNA
leptomycin B results in increased expression of TXNDC5 mRNA 1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane inhibits the reaction [leptomycin B results in increased expression of TXNDC5 mRNA]
leptomycin B results in decreased activity of XPO1 protein [leptomycin B results in decreased activity of XPO1 protein] which results in decreased export of SMAD4 protein
leptomycin B inhibits the reaction [arsenite inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]; leptomycin B inhibits the reaction [arsenite inhibits the reaction [XPO4 protein results in increased export of SMAD3 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [XPO4 protein results in increased export of SMAD3 protein]]
browse the term
